Core Insights - Shuttle Pharmaceuticals Holdings, Inc. has published a manuscript demonstrating the effectiveness of its HDAC inhibitor SP-1-303 in inhibiting the growth of estrogen receptor positive breast cancer cells [1][6] - The CEO of Shuttle Pharmaceuticals emphasized the potential of SP-1-303 as a promising therapeutic approach for treating estrogen receptor positive breast cancers through combined targeting of Class I HDACs and ATM [2] Company Overview - Founded in 2012 by faculty members of Georgetown University Medical Center, Shuttle Pharmaceuticals focuses on improving outcomes for cancer patients undergoing radiation therapy [5] - The company's mission is to enhance the effectiveness of radiation therapy while minimizing side effects, aiming to increase cancer cure rates and improve patient quality of life [5] Research and Development - The published manuscript titled "Dual-targeting class I HDAC inhibitor and ATM activator, SP-1-303, preferentially inhibits estrogen receptor positive breast cancer cell growth" was authored by Dr. Mira Jung and Dr. Scott Grindrod [6] - SP-1-303 is a selective Class I HDAC inhibitor that shows direct cellular toxicity in estrogen receptor positive breast cancer and enhances PD-L1 expression, suggesting potential for combination with immune checkpoint blockers [7]
Shuttle Pharma's Selective HDAC Inhibitor Exhibits ATM Activation and Modulation of ER Expression Resulting in Substantial Growth Inhibition of Estrogen Receptor Positive Breast Cancer Cells, as Reported in PLOS ONE